Self-Sampling by Adolescents at Home: Assessment of the Feasibility to Successfully Collect Blood Microsamples by Inexperienced Individuals
Boffel et al.
The finding, in our words
Adolescents collecting blood microsamples at home achieved varying success rates across six devices, with Minicollect tubes performing poorest. The confirmation that visual inspection alone was insufficient, by analytical variability, underscores the need for robust quality assessment before deploying any device in decentralised trials.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Dried VAMS and DBS samples collected at home and analysed after a median of three days showed poor agreement with standard venous or capillary blood for HbA1c monitoring. In contrast, wet VAMS samples analysed immediately demonstrated excellent agreement, indicating that sample drying and delayed analysis compromise reliability for decentralised HbA1c measurement.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
VAMS microsampling found no significant difference from venous blood for tacrolimus in paediatric patients; samples were stable for 14 days, with average difference between paired at-home samples of 0.12 ± 0.94 ng/mL.
The validated LC-MS/MS method showed similar pharmacokinetic profiles for albendazole and its metabolites across plasma, whole blood, dried blood spots and Mitra microsamples from hookworm-infected adolescents, supporting microsampling for paediatric pharmacokinetic studies. Mitra extraction proved more robust than dried blood spots during validation and is recommended for future albendazole pharmacokinetic work, despite higher albendazole sulfone concentrations observed in both microsampling devices compared with wet matrices.
A comparison of blood microsampling found that after 35 days, PFAS recovery changed by over 10% for five analytes using the Neoteryx hemaPEN and four using Whatman 903, but zero using the Neoteryx Mitra. The Mitra retained 45 of 49 PFAS within 70-130% recovery, showing its high stability for decentralised biomonitoring without contamination risks.